-
2
-
-
3242805224
-
Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections
-
Low DE, Felmingham D, Brown SD, Rangaraju M, Nusrat R. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. J Infect 2004;49:115-25.
-
(2004)
J Infect
, vol.49
, pp. 115-125
-
-
Low, D.E.1
Felmingham, D.2
Brown, S.D.3
Rangaraju, M.4
Nusrat, R.5
-
3
-
-
0036194907
-
Telithromycin: The first of the ketolides
-
DOI 10.1345/aph.1A038
-
Shain CS, Amsden GW. Telithromycin: the first of the ketolides. Ann Pharmacother 2002;36:452-64. DOI 10.1345/aph.1A038
-
(2002)
Ann Pharmacother
, vol.36
, pp. 452-464
-
-
Shain, C.S.1
Amsden, G.W.2
-
4
-
-
0042090159
-
Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment
-
Cantallobe C, Bhargava V, Sultan E, Vacheron F, Batista I, Montay G. Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment. Int J Antimicrob Agents 2003;22:112-21.
-
(2003)
Int J Antimicrob Agents
, vol.22
, pp. 112-121
-
-
Cantallobe, C.1
Bhargava, V.2
Sultan, E.3
Vacheron, F.4
Batista, I.5
Montay, G.6
-
5
-
-
0042358739
-
Ketolides: A new class of antibacterial agents for treatment of community-acquired respiratory tract infections in the primary care setting
-
Clark JP, Langston E. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in the primary care setting. Mayo Clin Proc 2003;78:1113-24.
-
(2003)
Mayo Clin Proc
, vol.78
, pp. 1113-1124
-
-
Clark, J.P.1
Langston, E.2
-
6
-
-
0019799332
-
A method for estimating the probability of adverse drug reactions
-
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
-
(1981)
Clin Pharmacol Ther
, vol.30
, pp. 239-245
-
-
Naranjo, C.A.1
Busto, U.2
Sellers, E.M.3
Sandor, P.4
Ruiz, I.5
Roberts, E.A.6
-
7
-
-
0029621846
-
Massive overdose of sustained-release verapamil: A case report and review of the literature
-
Ashraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained-release verapamil: a case report and review of the literature. Am J Med Sci 1995;310:258-63.
-
(1995)
Am J Med Sci
, vol.310
, pp. 258-263
-
-
Ashraf, M.1
Chaudhary, K.2
Nelson, J.3
Thompson, W.4
-
8
-
-
0007548201
-
Antihypertensive agents
-
Goldfrank LR, Flomenbaum NE, Lewin NA, eds. Norwalk, CT: Appleton & Lange
-
Lewin NA. Antihypertensive agents. In: Goldfrank LR, Flomenbaum NE, Lewin NA, eds. Goldfrank's toxicologic emergencies. 5th ed. Norwalk, CT: Appleton & Lange, 1994:704-8.
-
(1994)
Goldfrank's Toxicologic Emergencies. 5th Ed.
, pp. 704-708
-
-
Lewin, N.A.1
-
9
-
-
0032897280
-
Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil
-
Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 1999;47:545-52.
-
(1999)
Br J Clin Pharmacol
, vol.47
, pp. 545-552
-
-
Tracy, T.S.1
Korzekwa, K.R.2
Gonzalez, F.J.3
Wainer, I.W.4
-
10
-
-
0034904673
-
Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole
-
Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001;40:523-37.
-
(2001)
Clin Pharmacokinet
, vol.40
, pp. 523-537
-
-
Andersson, T.1
Hassan-Alin, M.2
Hasselgren, G.3
Rohss, K.4
-
11
-
-
0043124614
-
Drug interactions with angiotensin receptor blockers: A comparison with other antihypertensives
-
Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives. Drug Saf 2003;26:707-20.
-
(2003)
Drug Saf
, vol.26
, pp. 707-720
-
-
Unger, T.1
Kaschina, E.2
-
12
-
-
0032420063
-
Clinical pharmacokinetics of oxaprozin
-
Davies NM. Clinical pharmacokinetics of oxaprozin. Clin Pharmacokinet 1998;35:425-36.
-
(1998)
Clin Pharmacokinet
, vol.35
, pp. 425-436
-
-
Davies, N.M.1
-
13
-
-
0030783057
-
Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans
-
Chiba M, Xu X, Nishime JA, Balani SK, Lin JH. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos 1997;25:1022-31.
-
(1997)
Drug Metab Dispos
, vol.25
, pp. 1022-1031
-
-
Chiba, M.1
Xu, X.2
Nishime, J.A.3
Balani, S.K.4
Lin, J.H.5
-
14
-
-
0033924849
-
Drug interactions with cisapride: Clinical implications
-
Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000;39:49-75.
-
(2000)
Clin Pharmacokinet
, vol.39
, pp. 49-75
-
-
Michalets, E.L.1
Williams, C.R.2
-
15
-
-
19244365446
-
Oral erythromycin and the risk of sudden death from cardiac causes
-
Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96.
-
(2004)
N Engl J Med
, vol.351
, pp. 1089-1096
-
-
Ray, W.A.1
Murray, K.T.2
Meredith, S.3
Narasimhulu, S.S.4
Hall, K.5
Stein, C.M.6
-
16
-
-
0037342872
-
Drugs of the 21st century: Telithromycin (HMR 3647) - The first ketolide
-
Ackermann G, Rodloff AC. Drugs of the 21st century: telithromycin (HMR 3647) - the first ketolide. J Antimicrob Chemother 2003;51:497-511.
-
(2003)
J Antimicrob Chemother
, vol.51
, pp. 497-511
-
-
Ackermann, G.1
Rodloff, A.C.2
-
17
-
-
1242272026
-
Efficacy and tolerability of once-daily telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults
-
Dunbar LM, Hassman J, Tellier G. Efficacy and tolerability of once-daily telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48-62.
-
(2004)
Clin Ther
, vol.26
, pp. 48-62
-
-
Dunbar, L.M.1
Hassman, J.2
Tellier, G.3
-
18
-
-
0034851464
-
Clinical-pharmacological strategies to assess drug interaction potential during drug development
-
Kuhlmann J, Muck W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf 2001;24:715-25.
-
(2001)
Drug Saf
, vol.24
, pp. 715-725
-
-
Kuhlmann, J.1
Muck, W.2
|